Compounds with 5-ht1a activity useful for treating disorders of the outer retina
CA 2400639 C · Owner: Hellberg, Mark R. · Inventors: Hellberg, Mark R.; Kapin, Michael A.; Collier, Robert J. Jr.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compositions and methods for treating disorders of the outer retina with compounds with 5-HT1A agonist activity are disclosed. The disorder is selected from the group consisting of: AMD; RP and other forms of heredodegenerative retinal disease; retinal detachment and tears; macular pucker; ischemia affecting the outer retina; diabetic retinopathy; damage associated with laser therapy (grid, focal, and panretinal) including photodynamic therapy (PDT); trauma; surgical (retinal translocation subretinal surgery, or vitrectomy) or light-induced iatrogenic retinopathy; and preservation of retinal transplants. The compounds is selected from the group consisting of: tandospirone urapidil, …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 23, 2001 and granted August 16, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 23, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 23, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.